Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 2/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 2/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.45 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26344969 | 0.88 | RYR2 (0.61) | RYR2KCNH2CCR3CARM1PRMT6 | |
| SCHEMBL806929 | 0.87 | RYR2 (1.00) | RYR2KCNH2SIGMAR1 | |
| SCHEMBL6867427 | 0.77 | KCNH2 (0.74) | RYR2KCNH2 | |
| SCHEMBL13622077 | 0.75 | RYR2 (0.52) | RYR2MAPTALDH1A1TSHR | |
| SCHEMBL7558332 | 0.74 | RYR2 (0.53) | RYR2MAPTALDH1A1POLBKMT2A | |
| SCHEMBL13587293 | 0.74 | RYR2 (0.58) | RYR2KCNH2CCR3CARM1PRMT6 | |
| SCHEMBL6866909 | 0.73 | RYR2 (0.73) | RYR2KCNH2MEN1KMT2A | |
| SCHEMBL8248176 | 0.72 | CCR3 (0.63) | KCNH2CCR3CARM1PRMT6PRMT3 | |
| SCHEMBL13460725 | 0.71 | RYR2 (0.53) | RYR2CCR3CARM1PRMT6CYP1A2 | |
| SCHEMBL13309113 | 0.70 | RYR2 (0.68) | RYR2KCNH2SIGMAR1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230386615-A1 | BINDING SITE IN TYPE 1 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-30 | — | — | US | disclosed |
| US-20230386615-A1 | BINDING SITE IN TYPE 1 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-30 | — | — | US | disclosed |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-16 | — | — | US | disclosed |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-16 | — | — | US | disclosed |
| US-20230302013-A1 | METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-09-28 | — | — | US | disclosed |
| US-20230302013-A1 | METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-09-28 | — | — | US | disclosed |
| WO-2023070091-A1 | A METHOD OF TREATING ESSENTIAL TREMOR BY TARGETING LEAKY RyR1 CHANNELS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-2764867-A1 | Agents for preventing and treating disorders Involving modulation of the RYR receptors | The Trustees of Columbia University in the City of New York (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20140187536-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187536-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2008060332-A9 | METHODS FOR TREATING OR REDUCING MUSCLE FATIGUE | TRUSTESS OF COLUMBIA UNIVERSIT (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008060332-A2 | METHODS FOR TREATING OR REDUCING MUSCLE FATIGUE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008021432-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF CONDITIONS AFFECTING THE NERVOUS SYSTEM | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021439-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIAC HYPERTROPHY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007127145-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CARDIAC ARRHYTHMIA IN NON-HUMAN ANIMALS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-26 | — | — | US | disclosed |
| WO-2007024717-A2 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYR RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049572-A1 | Novel agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049572-A1 | Novel agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 165/4885CCR3 1774/4885 |
| US-20230302013-A1 | METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS | RYR2, RYR1, CACNB1 | RYR2 1/4885KCNH2 293/4885CCR3 4434/4885 |
| US-20070049572-A1 | Novel agents for preventing and treating disorders involving modulation of the RyR receptors | RYR2, RYR1, ATP2A1 | RYR2 1/4885KCNH2 315/4885CCR3 3346/4885 |
| US-20140187536-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | RYR2, RYR1, FKBP3 | RYR2 1/4885KCNH2 45/4885CCR3 4354/4885 |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | RYR2, RYR1, ATP2A2 | RYR2 1/4885KCNH2 420/4885CCR3 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.